Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tylofas Forte** is a marketed veterinary fixed-dose antimicrobial product manufactured by Zakfas Pharmaceuticals. Each mL contains tylosin tartrate 50 mg, colistin sulfate 10 mg, and dimetridazole 100 mg. Tylosin is a macrolide antibacterial that inhibits bacterial protein synthesis through the 50S ribosomal subunit; colistin is a polymyxin antibacterial that disrupts the outer membrane of susceptible Gram-negative bacteria through lipopolysaccharide binding; and dimetridazole is a nitroimidazole antiprotozoal and antibacterial agent that is reduced in anaerobic organisms to reactive metabolites that damage DNA. The public product listing does not specify the labeled animal species, indications, administration route, or dosage regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tylofas Forte.